The change will allow Medicare beneficiaries access to certain GLP-1 medications "outside of the Medicare Part D benefit coverage and payment flow," CMS said
*Correspondence: Gunda Herberth, [email protected] These authors share first authorship These authors share senior authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Researchers should consider established supplier reviews and, when possible, verify product identity and purity through third-party testing
A part of Watch Medier Global Clinical Lead, Clinical Development, Migraine & Pain Director, Drug Safety Operations Senior Safety Manager Pharmacokineticist, PK/PD Modelling & Simulation Medical Writer responsible for Clinical Disclosure Clinical Supply Manager You need to be a subscriber to read the rest of the article